Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
February 27, 2024 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Neurologists Report
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
February 22, 2024 15:04 ET | Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
February 21, 2024 09:00 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused...
Alterity.png
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
February 20, 2024 10:25 ET | ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
Parkinson’s Disease
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
February 16, 2024 10:40 ET | Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Research Nester Logo.jpg
Endoscopy Devices Market revenue to surpass USD 52 Billion by 2036, says Research Nester
February 13, 2024 06:30 ET | Research Nester
New York , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The global endoscopy devices market size is projected to grow at a CAGR of over 5% from 2024 to 2036. The market is expected to garner a revenue of USD...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024 16:02 ET | Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
MnM_logo_TM_JPG.JPG
Therapeutic Hypothermia Systems Market is Expected to Reach $396 Million | MarketsandMarkets™
February 07, 2024 07:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Therapeutic Hypothermia Systems market in terms of revenue was estimated to be worth $291 million in 2023 and is poised to reach $396 million by 2028,...
Research Nester Logo.jpg
Medical Imaging Market revenue to reach USD 60 Billion by 2033, says Research Nester
February 07, 2024 06:30 ET | Research Nester
New York , Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global medical imaging market size is projected to grow at a CAGR of over 6% from 2023 to 2033. The market is expected to garner a revenue of USD 60...